Cover Image
Market Research Report

Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025

Published by KuicK Research Product code 945622
Published Content info 1200 Pages
Delivery time: 1-2 business days
Price
Back to Top
Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025
Published: July 1, 2020 Content info: 1200 Pages
Description

"Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

  • Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
  • Insight on Cancer Drugs In Clinical Trials: 360 Drugs
  • Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
  • Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
  • Cancer Drug Price, Dosage & Sales Insight: 250 Graphs
  • Cancer Clinical Pipeline By Company, Indication & Phase

Cancer drug market in Japan is witnessing positive growth outlook similar to patterns observed at global levels. The domestic and multinational companies operating in Japan have launched several innovative products in the market driving the overall sales levels in recent years. The increasing geriatric population, R&D spending for new drug innovation, availability of targeted drug therapies are the prominent factors leading to above average growth of cancer drugs market in Japan. The future market growth for cancer drugs and therapies is expected to be almost 70% in absolute terms by 2025 as compare to 2018 levels.

Targeted therapy has the leading share in the Japan cancer drug market while the immunotherapy is the second leading type of therapy. This is due to the ability of targeted therapies to kill only malignant cells thereby exhibiting better treatment outcomes. In addition, elevated efficacy and higher survival rates associated with the use of targeted therapy drugs are other reasons that fuel the growth of the market. In the case of immunotherapy, it is the fastest growing segment in Japan pharmaceutical market as it is widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body, which makes them less toxic as compared to other modes of cancer therapies. Hormonal therapy and chemotherapy are not commonly used in Japan as chemotherapy has several adverse effects and hormonal therapy is not able to treat all type of cancers.

In Japan, prostate and lung cancer therapeutics will lead the cancer drug market in upcoming years, which is mainly due to presence of huge geriatric population of Japan. Currently, about 28% of the total population of Japan belongs to the age more than 65 years and this share is expected to increase in upcoming years. Further, the breast cancer drug market will also emerge as the leading segment of Japan caner drug market in near future as the cases of breast cancer is increasing rapidly in Japan. The overall Cancer cases in Japan are also rising and hence the demand of anticancer drugs is expected to increase rapidly in future years.

Japanese government will also play a prominent role in the rapid growth of cancer drug market by providing favorable policies framework for easy drug approval, production and marketing of products. A policy framework change is required in order to make drug approval process simpler so that the globally available products of leading MNCs can enter the Japanese market and are easily accessible to desired targeted population. In addition to this, it is also necessary to make the drug approval process faster so that the essential and highly effective drugs get approve on right time. As the leading regional companies of Japan is witnessing sales breakdown, the government of Japan can play a major role to encourage these companies for continuous production of the branded as well as generic anticancer drugs.

Several new drugs targeting different type of cancer are about to get approved by PMDA very soon, which will take this market segment to the next level. About 1617 cancer related clinical trials related to more than 350 cancer drugs are under investigation in Japan in which about 30% trials are in late development stage. The investments related to research and development is also increasing and many innovative cancer targeting therapies is expected to get approved in Japan, which will act as game changer in the treatment of cancer.

The future of Japanese cancer drug market seems to the sustain the past growth trends and will continue to its upward growth trajectory in coming years. Cancer drug market opportunity is expected to surpass US$ 15 Billion by 2025 driven by increasing number of clinical trials, availability of multiple products and the favorable steps undertaken by various stake holders of the pharmaceutical market. The Japan cancer drug market growth will take place at tremendous pace and this segment will emerge as an ocean of opportunities in near future.

Table of Contents

Table of Contents

1. Japan Cancer Drug Market Insight

  • 1.1. Overview
  • 1.2. Current Market Scenario

2. Japan - Cancer Prevalence & Statistics

  • 2.1. Overview
  • 2.2. By Cancer Type
    • 2.2.1. Colorectum Cancer
    • 2.2.2. Lung Cancer
    • 2.2.3. Stomach Cancer
    • 2.2.4. Prostate Cancer
    • 2.2.5. Breast Cancer
    • 2.3. By Gender & Age

3. Japan - Drug Approval & Regulation Landscape

  • 3.1. Japan - Drug Regulatory Agencies
    • 3.1.1. Ministry of Health, Labor & Welfare (MHLW)
    • 3.1.2. Pharmaceuticals and Medical Devices Agency (PMDA)
  • 3.2. Drug Approval Process
    • 3.2.1. New Drug Approval (NDA) Application Process
    • 3.2.2. Generic Drug approval Process
    • 3.2.3. Orphan Drug Approval

4. Japan - Drug Pricing & Reimbursement Policies

  • 4.1. Drug Pricing in Japan
    • 4.1.1. Pricing of New Pharmaceuticals
    • 4.1.2. Pricing of Generics & Biosimilars
  • 4.2. Reimbursement Policies

5. Japan Cancer Drug Market - Clinical Insight

  • 5.1. By Phase
  • 5.2. By Status
  • 5.3. By Cancer Type
    • 5.3.1. Breast Cancer
    • 5.3.2. Colorectal Cancer
    • 5.3.3. Prostate Cancer
    • 5.3.4. Lung Cancer
    • 5.3.5. Stomach Cancer

6. Japan Breast Cancer Drug Market - Availability, Dosage & Price Analysis

  • 6.1. HER2. inhibitors
    • 6.1.1. Herceptin
    • 6.1.2. Kadcyla
    • 6.1.3. Perjeta (Pertuzumab)
    • 6.1.4. Enhertu (Antibody Drug Conjugate)
    • 6.1.5. Tykerb (Lapatinib)
  • 6.2. Hormone Therapy
    • 6.2.1. Letrozole
    • 6.2.2. Anastrazole (Arimidex)
    • 6.2.3. Megestrol
    • 6.2.4. Faslodax (Fulvestrant)
    • 6.2.5. Toremifene
    • 6.2.6. Exemestane (Aromasin)
    • 6.3. CDK 4/6 Inhibitors
    • 6.3.1. Verzenio (Abemaciclib)
    • 6.3.2. Ibrance

7. Japan Prostate Cancer Drug Market - Availability, Dosage & Price Analysis

  • 7.1. Patented Drugs
    • 7.1.1. Xtandi (Enzalutamide)
    • 7.1.2. Erleada (Apalutamide)
    • 7.1.3. Nubeqa
    • 7.1.4. Xofigo (Radium Ra 223 dichloride)
  • 7.2. Generic Drugs
    • 7.2.1. Abiraterone
    • 7.2.2. Bicalutamide
    • 7.2.3. Nilutamide
    • 7.2.4. Flutamide

8. Japan Lung Cancer Drug Market - Availability, Dosage & Price Analysis

  • 8.1. Patented Drugs
    • 8.1.1. Alimta (Pemetrexed)
    • 8.1.2. Alecensa (Alectinib)
    • 8.1.3. Gilotrif
    • 8.1.4. Lorbrena
    • 8.1.5. Portrazza (Necitimumab)
    • 8.1.6. Rozlytrek
    • 8.1.7. Tagrisso
    • 8.1.8. Vizimpro (Dacomitinib)
    • 8.1.9. Xalkori (Crizotinib)
    • 8.1.10. Zykadia (Certinib)
  • 8.2. Generic Drugs
    • 8.2.1. Vinorelbine

9. Japan Colorectum Cancer Drug Market - Availability, Dosage & Price Analysis

  • 9.1. Patented drugs
    • 9.1.1. Lonsurf
    • 9.1.2. Vectibix (Panitumumab)
    • 9.1.3. Zaltrap
  • 9.2. Generic Drugs
    • 9.2.1. Irinotecan
    • 9.2.2. Oxaliplatin

10. Other Leading Cancer Drugs - Availability, Dosage, Price & Sales Analysis

  • 10.1. Avastin (Bevacizumab)
  • 10.2. Mabthera/Rituxan
  • 10.3. Tecentriq
  • 10.4. Opdivo
  • 10.5. Revlimid
  • 10.6. Keytruda
  • 10.7. Imbruvica

11. Japan Cancer Biosimilar Market - Availability, Dosage & Price Analysis

  • 11.1. Biosimilar of Avastin
  • 11.2. Biosimilars of Herceptin
  • 11.3. Rituxan's Biosimilar

12. Japan Cancer Drugs Market Dynamics

  • 12.1. Market Drivers
  • 12.2. Challenges to Overcome

13. Japan Cancer Drug Market Future Outlook

14. Japan Cancer Clinical Pipeline By Company, Indication & Phase

  • 14.1. Research
  • 14.2. Preclinical
  • 14.3. Clinical
  • 14.4. Phase-I
  • 14.5. Phase-I/II
  • 14.6. Phase-II
  • 14.7. Phase-II/III
  • 14.8. Phase-III
  • 14.9. Preregistration
  • 14.10. Registered

15. Japan Marketed Cancer Drug Clinical Insight by Companies & Indication

16. Competitive Landscape

  • 16.1. Regional Companies
    • 16.1.1. Takeda Pharmaceuticals
    • 16.1.2. Daiichi Sankyo
    • 16.1.3. Kyowa Kirin
    • 16.1.4. Mitsubishi Taneba Pharma Co.
    • 16.1.5. Otsuka Pharmaceutical Co. Ltd.
    • 16.1.6. Eisai Co. Ltd.
    • 16.1.7. Astellas Pharma
  • 16.2. Multinational Company
    • 16.2.1. Novartis
    • 16.2.2. Amgen
    • 16.2.3. Eli Lilly
    • 16.2.4. Merck
    • 16.2.5. Pfizer
    • 16.2.6. GlaxoSmithKline plc
    • 16.2.7. Roche

List of Figures

  • Figure 1-1: Japan - Per Capita Healthcare Expenditure (US$/JPY), 2017 & 2018
  • Figure 1-2: Japan - Heath care Expenditure (US$/JPY Billion), 2017 & 2018
  • Figure 1-3: Japan - Per Capita Heath care Expenditure by Age (US$/JPY), 2018
  • Figure 1-4: Global - Pharmaceutical Market Size by Leading Countries (US$ Billion), 2018
  • Figure 1-5: Global - Pharmaceutical Market Size by Leading Countries (US$ Billion), 2018
  • Figure 1-6: Estimated Cancer Cases - Global v/s Japan (Million), 2020
  • Figure 1-7: Japan - Cancer Drug Market Size (US$ Billion), 2018 - 2025
  • Figure 1-8: Cancer Drug Market Size - Japan v/s Global (US$ Billion), 2019
  • Figure 1-9: Cancer Drug Market Size - Japan v/s Global (US$ Billion), 2019
  • Figure 1-10: Japan - Volume Share of Generics (%), 2011 , 2015, 2017 & 2020
  • Figure 2-1: Japan - Newly Diagnosed Cancer Cases, 2018, 2020 & 2025
  • Figure 2-2: Japan - Cancer Deaths Statistics, 2018, 2020 & 2025
  • Figure 2-3: Age Standardized Cancer Incidence Rate - Japan v/s Global Average (Per 100,000), 2018
  • Figure 2-4: Age Standardized Cancer Mortality Rate - Japan v/s Global Average (Per 100,000), 2018
  • Figure 2-5: Japan - Newly Diagnosed Cancer Cases by Type, 2018
  • Figure 2-6: Japan - Newly Diagnosed Cancer Cases by Type (%), 2018
  • Figure 2-7: Japan - Cancer Related Deaths by Type, 2018
  • Figure 2-8: Japan - Newly Diagnosed Colorectum Cancer Cases, 2018, 2020 & 2025
  • Figure 2-9: Japan - Newly Diagnosed Colorectum Cancer Cases by Type, 2018
  • Figure 2-10: Japan -Colorectum Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-11: Japan - Age Standardized Colorectum Cancer Incidence & Mortality Rate (Per 100,000), 2018
  • Figure 2-12: Japan - Newly Diagnosed Lung Cancer Cases, 2018, 2020 & 2025
  • Figure 2-13: Japan -Lung Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-14: Japan - Age Standardized Lung Cancer Incidence & Mortality Rate (Per 100,000), 2018
  • Figure 2-15: Japan - Newly Diagnosed Stomach Cancer Cases, 2018, 2020 & 2025
  • Figure 2-16: Japan - Stomach Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-17: Japan - Age Standardized Stomach Cancer Incidence & Mortality Rate (Per 100,000), 2018
  • Figure 2-18: Japan - Newly Diagnosed Prostate Cancer Cases, 2018, 2020 & 2025
  • Figure 2-19: Japan - Prostate Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-20: Japan - Age Standardized Prostate Cancer Incidence & Mortality Rate (Per 100,000), 2018
  • Figure 2-21: Japan - Newly Diagnosed Breast Cancer Cases, 2018, 2020 & 2025
  • Figure 2-22: Japan - Breast Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-23: Japan - Age Standardized Breast Cancer Incidence & Mortality Rate (Per 100,000), 2018
  • Figure 2-24: Japan - Newly Diagnosed Cancer Cases by Gender, 2018
  • Figure 2-25: Japan - Cancer Deaths by Gender, 2018
  • Figure 2-26: Japan - Age Standardized Cancer Incidence Rate by Gender (Per 100,000), 2018
  • Figure 2-27: Japan - Age Standardized Cancer Mortality Rate by Gender (Per 100,000), 2018
  • Figure 2-28: Japan - Estimated Number of Newly Diagnosed Cancer Cases in Males, 2020 & 2025
  • Figure 2-29: Japan - Estimated Number of Newly Diagnosed Cancer Cases in Females, 2020 & 2025
  • Figure 2-30: Japan - Male Cancer Cases by Type, 2018
  • Figure 2-31: Japan - Male Cancer Cases by Type, 2018
  • Figure 2-32: Japan - Male Cancer Cases by Type, 2018
  • Figure 2-33: Japan - Female Cancer Cases by Type, 2018
  • Figure 2-34: Japan - Female Cancer Cases by Type (%), 2018
  • Figure 2-35: Japan - Female Cancer Cases by Type, 2018
  • Figure 2-36: Japan - Newly Diagnosed Cancer Cases by Age, 2018
  • Figure 2-37: Japan - Newly Diagnosed Cancer Cases by Age (%), 2018
  • Figure 2-38: Japan - Newly Diagnosed Cancer Cases by Age, 2018
  • Figure 2-39: Japan - Newly Diagnosed Cancer Cases by Age (%), 2018
  • Figure 3-1: Japan - PMDA Review Process for Drugs & Medical Devices
  • Figure 3-2: Japan - PMDA Regulatory System for Practical Application of Cellular & Tissue Based Product
  • Figure 3-3: Japan - Organisation of PMDA
  • Figure 3-4: Japan - New Drug Marketing Approval Process
  • Figure 4-1: Outline of Pricing New Pharmaceuticals
  • Figure 4-2: Japan - Premium Applied During Price Fixation of New Pharmaceuticals
  • Figure 4-3: Japan - Components of Cost Calculation Method
  • Figure 4-4: Japan - Price of New Generic & Oral Generic with more than 10 Brands v/s Original Product (%), April'2020
  • Figure 4-5: Japan - Price of Biotechnological & Chemically derived Biosimilars v/s Original Products
  • Figure 4-6: Japan: Price Reduction of Branded Drugs by Generic Replacement Rate (%)
  • Figure 5-1: Japan - Number of Clinical Trial related to Cancer v/s Total, April'2020
  • Figure 5-2: Japan - Number of Clinical Trial related to Cancer v/s Total (%), April'2020
  • Figure 5-3: Japan - Number of Clinical Trial by Phase, April'2020
  • Figure 5-4: Japan - Number of Clinical Trials by Phase (%), April'2020
  • Figure 5-5: Japan - Number of Drug In Clinical Trials by Phase, 2020 till 2025
  • Figure 5-6: Japan - Number of Drug In Clinical Trials by Phase, 2020 till 2025
  • Figure 5-7: Japan - Number of Clinical Trial by Status, April'2020
  • Figure 5-8: Japan - Number of Breast Cancer Clinical Trial by Phase, April'2020
  • Figure 5-9: Japan - Number of Breast Cancer Clinical Trial by Phase (%), April'2020
  • Figure 5-10: Japan - Number of Breast Cancer Clinical Trial by Status, April'2020
  • Figure 5-11: Japan - Number of Colorectum Cancer Clinical Trial by Phase, April'2020
  • Figure 5-12: Japan - Number of Colorectum Cancer Clinical Trial by Phase (%), April'2020
  • Figure 5-13: Japan - Number of Colorectum Cancer Clinical Trial by Status, April'2020
  • Figure 5-14: Japan - Number of Prostate Cancer Clinical Trial by Phase, April'2020
  • Figure 5-15: Japan - Number of Colorectum Cancer Clinical Trial by Phase (%), April'2020
  • Figure 5-16: Japan - Number of Prostate Cancer Clinical Trial by Status, April'2020
  • Figure 5-17: Japan - Number of Lung Cancer Clinical Trial by Phase, April'2020
  • Figure 5-18: Japan - Number of Lung Cancer Clinical Trial by Phase (%), April'2020
  • Figure 5-19: Japan - Number of Lung Cancer Clinical Trial by Status, April'2020
  • Figure 5-20: Japan - Number of Stomach Cancer Clinical Trial by Phase, April'2020
  • Figure 5-21: Japan - Number of Lung Cancer Clinical Trial by Phase (%), April'2020
  • Figure 5-22: Japan - Number of Lung Cancer Clinical Trial by Status, April'2020
  • Figure 6-1: Breast Cancer Drug Market Size - Global v/s Japan (US$ Billion), 2019
  • Figure 6-2: Breast Cancer Drug Market Size - Global v/s Japan (%), 2019
  • Figure 6-3: Herceptin - Approval Year by Cancer Type
  • Figure 6-4: Herceptin - FDA approval & PMDA Approval Year
  • Figure 6-5: Herceptin - Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$/JPY), June'2020
  • Figure 6-6: Herceptin - Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg), June'2020
  • Figure 6-7: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$/JPY), June'2020
  • Figure 6-8: Herceptin - Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), January'2020
  • Figure 6-9: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$/JPY), January'2020
  • Figure 6-10: Japan - Herceptin Annual Sales Value (US$/JPY Million), 2017 - 2019
  • Figure 6-11: Japan - Herceptin Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 6-12: Japan - Herceptin Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 6-13: Kadcyla - FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer
  • Figure 6-14; Kadcyla - Price for Single Unit of 100mg & 150mg Intravenous Powder for Injection (US$), June'2020
  • Figure 6-15: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks), June'2020
  • Figure 6-16: Kadcyla - Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer (US$/JPY), June'2020
  • Figure 6-17: Kadcyla - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2), June'2020
  • Figure 6-18: Perjeta - FDA & PMDA Approval Year
  • Figure 6-19: Perjeta - Patent Expiration Year by Region
  • Figure 6-20: Perjeta - Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$/JPY), June'2020
  • Figure 6-21: Perjeta - Initial & Maintenance Dose for Breast Cancer Treatment (mg/ 3 weeks), June'2020
  • Figure 6-22: Perjeta - Minimum & Maximum Treatment Cost for Breast Cancer (US$/JPY), June'2020
  • Figure 6-23: Perjeta - Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$/JPY), January'2020
  • Figure 6-24: Japan - Perjeta Annual Sales Value (US$/JPY Million), 2017 - 2019
  • Figure 6-25: Japan - Perjeta Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 6-26: Japan - Perjeta Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 6-27: Enhertu - FDA & PMDA Approval Year
  • Figure 6-28: Enhertu - Disease Control, Tumor Shrinkage & Disease Elimination Rate (%)
  • Figure 6-29: Enhertu - Average Cost of Single Treatment Cycle & Annual Treatment Cost of Breast Cancer (US$/JPY), June'2020
  • Figure 6-30: Enhertu - Recommended Dose & Dose after Reduction (mg/Kg), June'2020
  • Figure 6-31: Tykerb - FDA & Japan Approval Year
  • Figure 6-32: Tykerb - Patent Issue & Expiration Year
  • Figure 6-33: Tykerb - Price for 150 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April'2020
  • Figure 6-34: Tykerb - for HER2+ & HER2+ Metastatic Breast Cancer (mg per day), April'2020
  • Figure 6-35: Tykerb - Treatment & Rest Phase in Single Treatment Cycle (Days)
  • Figure 6-36: Letrozole - FDA & PMDA Approval Year
  • Figure 6-37: Letrozole - Price for a Supply of 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 6-38: Letrozole - Price for a Supply of 50 Tablets & Price per Unit Tablet (US$), June'2020
  • Figure 6-39: Letrozole - Price for a Supply of 90 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 6-40: Letrozole - Price for a Supply of 1000 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 6-41: Femara - Price for a Supply of 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 6-42: Letrozole - Daily, Monthly & Annual Treatment Cost using Branded & Generic Letrozole (US$), June'2020
  • Figure 6-43: Anastarzole - FDA & Generic Approval Year
  • Figure 6-44: Anastrazole - Price for Various Supplies of 1mg Tablet (US$/JPY), June'2020
  • Figure 6-45: Arimidex - Price for 30 Tablet Supply & Price Per Unit Tablet (US$/JPY), June'2020
  • Figure 6-46: Anastrazole - Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020'January
  • Figure 6-47: Armidex - Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020'January
  • Figure 6-48: Megastrol - FDA & Generic Approval Year
  • Figure 6-49: Megastrol - Price for Various Supplies of 40mg/ml Oral Suspension (US$/JPY), June'2020
  • Figure 6-50: Megastrol - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$/JPY), June'2020
  • Figure 6-51: Megace ES - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$/JPY), June'2020
  • Figure 6-52: Megastrol - Price for Supply of 100 Tablets & Price per Unit of 20mg Tablet (US$/JPY), June'2020
  • Figure 6-53: Megastrol - Price for Supply of 100, 250 & 500 Tablets of 40mg (US$/JPY), June'2020
  • Figure 6-54: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg/ml Oral Suspension (US$), June'2020
  • Figure 6-55: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg Oral Tablet (US$), June'2020
  • Figure 6-56: Fulvestrant - FDA & PMDA Approval Year
  • Figure 6-57: Fulvestrant - Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$/JPY), June'2020
  • Figure 6-58: Faslodex - Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$/JPY), June'2020
  • Figure 6-59: Fulvestrant - Number of Dose Administration in Initial & Subsequent Months, January'2020
  • Figure 6-60: Fulvestrant - Treatment Cost of Initial & Subsequent Months (US$), January'2020
  • Figure 6-61: Fulvestrant - Treatment Cost of Initial & Subsequent Year (US$), January'2020
  • Figure 6-62: Faslodex - Treatment Cost of Initial & Subsequent Months (US$), January'2020
  • Figure 6-63: Faslodex - Treatment Cost of Initial & Subsequent Year (US$), January'2020
  • Figure 6-64: Toremifene - FDA & First Generic Approval Year
  • Figure 6-65: Toremifene - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 6-66: Fareston - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 6-67: Toremifene - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020'January
  • Figure 6-68: Fareston - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020'January
  • Figure 6-69: Exemestane - FDA & First Generic Approval Year
  • Figure 6-70: Exemestane - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 6-71: Aromasin - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 6-72: Exemestane - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020'January
  • Figure 6-73: Aromasin - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020'January
  • Figure 6-74: Verzenio - FDA & PMDA Approval Year
  • Figure 6-75: Verzenio - Patent Issue & Expiration Year
  • Figure 6-76: Verzenio - Price for a Supply of 14 Tablets & Price per unit of Tablet (US$/JPY), June'2020
  • Figure 6-77: Verzenio - Recommanded Dose Modification for Adverse Effects in Monotherapy (mg)
  • Figure 6-78: Verzenio - Recommanded Dose Modification for Adverse Effects in Combinational Therapy (mg)
  • Figure 6-79: Ibrance - FDA & PMDA Approval Year
  • Figure 6-80: Ibrance - Year of Assigning & Expiration of Different Patents
  • Figure 6-81: Ibrance - Price for a Supply of 21 Capsules & Per Unit Cost of Ibrance Capsules (US$/JPY), June'2020
  • Figure 6-82: Ibrance - Treatment Cycle of Ibrance using 1 Capsule/Day (Days)
  • Figure 6-83: Ibrance - Recommanded Dose Modification for Adverse effects (mg)
  • Figure 7-1: Xtandi - FDA & Japan Approval Year
  • Figure 7-2: Xtandi - Patent Issue & expiration Year
  • Figure 7-3: Xtandi - Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April'2020
  • Figure 7-4: Xtandi - Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April'2020
  • Figure 7-5: Xtandi - Cost of Single Capsule & Daily Treatment Cost (JPY/US$), April'2020
  • Figure 7-6: Erleada - FDA & Japan Approval Year
  • Figure 7-7: Erleada - Aragon related Patent Issue & expiration Year
  • Figure 7-8: Erleada - University of California related Patent Issue & expiration Year
  • Figure 7-9: Erleada - Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April'2020
  • Figure 7-10: Erleada - Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April'2020
  • Figure 7-11: Nubeqa - FDA & Japan Approval Year
  • Figure 7-12: Nubeqa - Aragon related Patent Issue & Expiration Year
  • Figure 7-13: Nubeqa - Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April'2020
  • Figure 7-14: Nubeqa - Price of Single Tablet & Daily Treatment Cost (JPY/US$), April'2020
  • Figure 7-15: Xofigo - FDA & Japan Approval Year
  • Figure 7-16: Xofigo - Patent Issue & expiration Year
  • Figure 7-17: Xofigo - Duration of One Treatment Cycle & Full Treatment Duration for Prostate Cancer (Weeks), April'2020
  • Figure 7-18: Abiraterone - FDA & PMDA Approval Year
  • Figure 7-19: Aberaterone - Price of 30 Tablets & Price per unit of 250mg Tablet (US$/JPY), June'2020
  • Figure 7-20: Aberaterone - Price of 120 Tablets & Price per Unit of 250mg Tablet (US$/JPY), June'2020
  • Figure 7-21: Zytiga - Price of 120 Tablets & Price per unit of 250mg Tablet (US$/JPY), June'2020
  • Figure 7-22: Zytiga - Price of 60 Tablets & Price per Unit of 500mg Tablet (US$/JPY), June'2020
  • Figure 7-23: Abiraterone - Treatment Cost Comparision of Metastatic High-risk CSPC Using Branded & Generic Tablet (US$), January'2020
  • Figure 7-24: Abiraterone - Treatment Cost Comparision of Metastatic CSPC Using Branded & Generic Tablet (US$), January'2020
  • Figure 7-25: Bicalutamide - FDA & First Generic Approval Year
  • Figure 7-26: Bicalutamide - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 7-27: Casodex - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 7-28: Bicalutamide - Price of 100 Tablets & Price per Unit of 50mg Tablet (US$/JPY), June'2020
  • Figure 7-29: Bicalutamide - Price of 500 Tablets & Price per Unit of 50mg Tablet (US$/JPY), June'2020
  • Figure 7-30: Bicalutamide - Treatment Cost Comparision of Prostate Cancer Using Branded & Generic Tablet (US$), January'2020
  • Figure 7-31: Nilutamide - FDA & First Generic Approval Year
  • Figure 7-32: Nilutamide - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 7-33: Nilandron - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June'2020
  • Figure 7-34: Nilutamide - Initial & Maintenance Dose for Prostate Cancer Treatment (mg/day)
  • Figure 7-35: Nilutamide - Comparision of Initial Month Treatment Cost of Prostate Cancer Using Branded & Generic Tablet (US$), June'2020
  • Figure 7-36: Nilutamide - Comparision of Maintenence Month Treatment Cost of Prostate Cancer Using Branded & Generic Tablet (US$), June'2020
  • Figure 7-37: Flutamide - FDA & First Generic Approval Year
  • Figure 7-38: Flutamide - Price for 180 Capsules & Price per Unit Capsule (US$/JPY), June'2020
  • Figure 7-39: Eulexin - Price for 180 Capsules & Price per Unit Capsule (US$/JPY), June'2020
  • Figure 7-40: Flutamide - Comparision of Daily, Monthly & Annual Treatment of Prostate Cancer Using Branded & Generic Capsule (US$), January'2020
  • Figure 8-1: Alimta - FDA & Japan Approval Year
  • Figure 8-2: Alimta - Patent Issue & expiration Year
  • Figure 8-3: Alimta - Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April'2020
  • Figure 8-4: Alimta - Number of Treatment Cycle Required in Combination with Pembtrolizumab & Cisplatin , April'2020
  • Figure 8-5: Alecensa - FDA & Japan Approval Year
  • Figure 8-6: Alecensa - Patent Issue & expiration Year
  • Figure 8-7: Alecensa - Price for 240 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April'2020
  • Figure 8-8: Alecensa - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 8-9: Gilotrif - FDA & Japan Approval Year
  • Figure 8-10: Gilotrif - Patent Issue & expiration Year
  • Figure 8-11: Gilotrif - Price for 30 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April'2020
  • Figure 8-12: Gilotrif - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 8-13: Iressa - FDA & Japan Approval Year
  • Figure 8-14: Iressa - Price for 30 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April'2020
  • Figure 8-15: Lorbrena - FDA Approval, Japan Approval & Patent expiration Years
  • Figure 8-16: Lorbrena - Price for 30 Tablet Supply & Price per unit of 25mg Oral Tablet (JPY/US$), April'2020
  • Figure 8-17: Lorbrena - Price for 30 Tablet Supply & Price per unit of 100 mg Oral Tablet (JPY/US$), April'2020
  • Figure 8-18: Lorbrena - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 8-19: Portrazza - FDA & Japan Approval Year
  • Figure 8-20: Portrazza - Price for 50 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April'2020
  • Figure 8-21: Portrazza - Cost of Single Treatment Cycle & Annual Treatment Cost of NSCLC (JPY/US$), April'2020
  • Figure 8-22: Rozlytrek - FDA Approval, Japan Approval & Patent Expiration Year
  • Figure 8-23: Rozyltrek - Price for 30 Capsules Supply & Price per Unit of 100 mg Oral Tablet (JPY/US$), April'2020
  • Figure 8-24: Rozyltrek - Price for 90 Capsules Supply & Price per unit of 200 mg Oral Tablet (JPY/US$), April'2020
  • Figure 8-25: Rozyltrek - Pediatric Dose by Surface Area (mg), April'2020
  • Figure 8-26: Tagrisso - FDA & Japan Approval Year
  • Figure 8-27: Tagrisso - Patent Issue & Expiration Year
  • Figure 8-28: Tagrisso - Price for 30 Tablet Supply & Price per Unit of 200 mg Oral Tablet (JPY/US$), April'2020
  • Figure 8-29: Tagrisso - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 8-30: Vizimpro - FDA & Japan Approval Year
  • Figure 8-31: Vizimpro - Patent Issue & Expiration Year
  • Figure 8-32: Vizimpro - Price for 30 Tablet Supply & Price per Unit of 200 mg Oral Tablet (JPY/US$), April'2020
  • Figure 8-33: Vizimpro - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 8-34: Xalkori - FDA & Japan Approval Year
  • Figure 8-35: Xalkori - Patent Issue & Expiration Year
  • Figure 8-36: Xalkori - Price for 60 Capsule Supply & Price per Unit of Oral Capsule (JPY/US$), April'2020
  • Figure 8-37: Zykadia - FDA & Japan Approval Year
  • Figure 8-38: Zykadia - Patent Expiration Year by Assignee
  • Figure 8-39: Zykadia - Price for 84 Capsules Supply & Price per Unit of Oral Capsule (JPY/US$), April'2020
  • Figure 8-40: Zykadia - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 8-41: Vinorelbine - FDA & First Generic Approval Year
  • Figure 8-42: Vinorelbine - Price for 5ml Supply & Price per ml of Intravenous Solution (US$/JPY), June'2020
  • Figure 8-43: Vinorelbine - Price for 5ml Supply & Price per ml of Intravenous Solution (US$/JPY), June'2020
  • Figure 8-44: Vinorelbine Monotherapy - Comparision of Treatment Cost of NSCLC Using Branded & Generic Intravenous Solution (US$), January'2020
  • Figure 8-45: Vinorelbine - Combinational Dose with 100mg/m2 and 120 mg/m2 Cisplatin (mg/m2), January'2020
  • Figure 9-1: Lonsurf - FDA Approval, Japan Approval & Patent Expiration Year
  • Figure 9-2: Lonsurf - Price for Various Supplies of 6.14 mg-15 mg Tablet (JPY/US$), April'2020
  • Figure 9-3: Lonsurf - Price for Various Supplies of 8.19mg-20mg Tablet (JPY/US$), April'2020
  • Figure 9-4: Lonsurf - Recommended Dose by Surface Area (mg per day)
  • Figure 9-5: Vectibix - FDA & Japan Approval Year
  • Figure 9-6: Vectibix - Price for 5 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April'2020
  • Figure 9-7: Vectibix - Price for 20 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April'2020
  • Figure 9-8: Zaltrap - FDA & Japan Approval Year
  • Figure 9-9: Zaltrap - Price for 4 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April'2020
  • Figure 9-10: Zaltrap - Price for 8ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April'2020
  • Figure 9-11: Irinotecan - FDA & First Generic Approval Year
  • Figure 9-12: Irinotecan - Price for Various Supplies of Intravenous Solution (US$/JPY), June'2020
  • Figure 9-13: Camptosar - Price for Various Supplies of Intravenous Solution (US$/JPY), June'2020
  • Figure 9-14: Irinotecan - Minimum & Maximum Duration of Treatment Cycle (Weeks), January '2020
  • Figure 9-15: Oxaliplatin - FDA & PMDA Approval Year
  • Figure 9-16: Oxaliplatin - Price of 50 mg & 100 mg Intravenous Powder for Injection (US$/JPY), June'2020
  • Figure 9-17: Oxaliplatin - Price of 10ml & 1ml Intravenous Solution for Injection (US$/JPY), June'2020
  • Figure 9-18: Eloxatin - Price of 10ml & 1ml Intravenous Solution for Injection (US$/JPY), June'2020
  • Figure 9-19: Eloxatin - Price of 20ml & 1ml Intravenous Solution for Injection (US$/JPY), June'2020
  • Figure 9-20: Oxaplatin - Duration of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (Weeks), 2020'January
  • Figure 10-1: Avastin - FDA & PMDA Approval Year
  • Figure 10-2: Avastin - Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$/JPY), June'2020
  • Figure 10-3: Avastin - Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$/JPY), June'2020
  • Figure 10-4: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$/JPY), June'2020
  • Figure 10-5: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$/JPY), June'2020
  • Figure 10-6: Avastin - Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), June'2020
  • Figure 10-7: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$/JPY), June'2020
  • Figure 10-8: Japan - Avastin Annual Sales Value (US$/JPY Million), 2017 - 2019
  • Figure 10-9: Japan - Avastin Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 10-10: Japan - Avastin Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 10-11: Gazyva - FDA Approval Year by Indication
  • Figure 10-12: Rituxan - FDA & Japan Approval Year
  • Figure 10-13: Rituxan - Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$/JPY), June'2020
  • Figure 10-14: Rituxan - Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$/JPY), June'2020
  • Figure 10-15: Rituxan - Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$/JPY), June'2020
  • Figure 10-16: Rituxan - Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$/JPY), June'2020
  • Figure 10-17: Rituxan - Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June'2020
  • Figure 10-18: Japan - Rituxan Annual Sales Value (US$/JPY Million), 2017 - 2019
  • Figure 10-19: Japan - Rituxan Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 10-20: Japan - Rituxan Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 10-21: Tecentriq - FDA & Japan Approval Year
  • Figure 10-22: Tecentriq - Price for 14ml Supply & Price per ml of 840mg/14ml Intravenous Injection (US$/JPY), June'2020
  • Figure 10-23: Tecentriq - Price for 20ml Supply & Price per ml of 1200mg/20ml Intravenous Injection (US$/JPY), June'2020
  • Figure 10-24: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/m2 Week Dose (US$/JPY), June'2020
  • Figure 10-25: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$/JPY), June'2020
  • Figure 10-26: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$/JPY), June'2020
  • Figure 10-27: Japan - Tecentriq Annual Sales Value (US$/JPY Million), 2017 - 2019
  • Figure 10-28: Japan - Tecentriq Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 10-29: Japan - Tecentriq Quarterly Sales Value (US$/JPY Million), 2019
  • Figure 10-30: Opdivo - FDA & Japan Approval Year
  • Figure 10-31: Opdivo - Patent Expiration Year by Region
  • Figure 10-32: Opdivo - Price for 4ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June'2020
  • Figure 10-33: Opdivo - Price for 10 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June'2020
  • Figure 10-34: Opdivo - Price for 20 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June'2020
  • Figure 10-35: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$/JPY), June'2020
  • Figure 10-36: Opdivo Combination - Dose for Management of Melanoma & Renal Cell Carcinoma (mg/3 Weeks)), June'2020
  • Figure 10-37: Revlimid - FDA & Japan Approval Year
  • Figure 10-38: Revlimid - FDA Approval Year by Indication
  • Figure 10-39: Revlimid - FDA Approval & Patent Expiration Year
  • Figure 10-40: Revlimid - Price for 28 capsules & 100 Capsules of 2.5mg, 5mg & 10mg Capsules (US$/JPY), June'2020
  • Figure 10-41: Revlimid - Price for 21 capsules & 100 Capsules of 15mg, 20mg & 25mg Capsules (US$/JPY), June'2020
  • Figure 10-42: Revlimid - Recommended Daily Dose by Indications (mg)
  • Figure 10-43: Keytruda - FDA & Japan Approval Year
  • Figure 10-44: Keytruda - Patent Expiration Year by Region
  • Figure 10-45: Keytruda - Price for 4ml & 8ml Supply & Price per ml of Intravenous Injection (US$/JPY), June'2020
  • Figure 10-46: Keytruda - Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), June'2020
  • Figure 10-47: Keytruda - Cost of Single and Full Treatment using Powder of Injection (US$/JPY), June'2020
  • Figure 10-48: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$/JPY), June'2020
  • Figure 10-49: Ibrutinib - FDA Approval Year by Indication
  • Figure 10-50: Ibrutinib - FDA Approval Year by Dosage Form
  • Figure 10-51: Imbruvica - FDA & Japan Approval Year
  • Figure 10-52: Imbruvica - Price for 90 & 120 Capsule Supplies of 140mg (US$/JPY), June'2020
  • Figure 10-53: Imbruvica Capsule - Price for 28 Capsule & Price per Unit Capsule of 70mg (US$/JPY), June'2020
  • Figure 10-54: Imbruvica Tablet - Price for 28 Tablets & Price per Unit Tablet of Various Doses (US$/JPY), June'2020
  • Figure 10-55: Imbruvica - Recommended Daily Dose by Indication (mg), May'2020
  • Figure 11-1: Avastin's Biosimilar - FDA Approval Year
  • Figure 11-2: Mvasi - Price for 4ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April'2020
  • Figure 11-3: Mvasi - Price for 16 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April'2020
  • Figure 11-4: Zirabev - Price for 4ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April'2020
  • Figure 11-5: Zirabev - Price for 16 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April'2020
  • Figure 11-6: Japan - Avastin's Biosimilar PMDA Approval Year
  • Figure 11-7: Herceptin's Biosimilar - FDA Approval Year
  • Figure 11-8: Japan - Herceptin's Biosimilar PMDA Approval Year
  • Figure 11-9: Kanjati: Price for 150 mg and 420 mg Supply of Intravenous Powder for Injection (JPY/US$), April'2020
  • Figure 11-10: Trazimera: Price for a supply of 150 mg & 420mg Intravenous Powder of (JPY/US$), April'2020
  • Figure 11-11: Rituxan Biosimilar - FDA Approval Year
  • Figure 11-12: Japan - Rituxan Biosimilar PMDA Approval Year
  • Figure 11-13: Ruxience - Price for a supply of 10 ml & Price per ml of Intravenous Solution (JPY/US$), April'2020
  • Figure 11-14: Ruxience - Price for a supply of 10 ml & Price per ml of Intravenous Solution (JPY/US$), April'2020
  • Figure 12-1: Japan Cancer Drug Market Drivers
  • Figure 12-2: Challenges for Japan Cancer Drugs Market
Back to Top